TCGA-GU-A764-01A-11R-A352-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 20.03942181
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.480
- ALLOGRAFT_REJECTION+0.470
- COAGULATION+0.450
- IL6_JAK_STAT3_SIGNALING+0.380
- INFLAMMATORY_RESPONSE+0.370
- TNFA_SIGNALING_VIA_NFKB+0.340
- E2F_TARGETS+0.330
- ANGIOGENESIS+0.300
- APICAL_JUNCTION+0.280
- MYOGENESIS+0.280
Top 10 suppressed
- PROTEIN_SECRETION-0.410
- ADIPOGENESIS-0.300
- OXIDATIVE_PHOSPHORYLATION-0.290
- FATTY_ACID_METABOLISM-0.280
- MYC_TARGETS_V2-0.280
- ANDROGEN_RESPONSE-0.240
- PEROXISOME-0.220
- UNFOLDED_PROTEIN_RESPONSE-0.220
- CHOLESTEROL_HOMEOSTASIS-0.190
- MITOTIC_SPINDLE-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG133 | — | — | 0.828 |
| 2 | R101 | — | — | 0.821 |
| 3 | R107 | — | — | 0.815 |
| 4 | BS_1J2WQ08M | Posterior Fossa Ependymoma | — | 0.814 |
| 5 | MNG276 | — | — | 0.813 |
| 6 | MDT-AP-0380 | Med | Medulloblastoma | 0.811 |
| 7 | MNG1166 | — | — | 0.810 |
| 8 | TCGA-OR-A5J8-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.807 |
| 9 | MDT-AP-0342 | Med | Medulloblastoma | 0.805 |
| 10 | TCGA-C8-A8HQ-01A-11R-A36F-07 | — | C | 0.805 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.480 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.470 | Idelalisib | — uncovered |
| COAGULATION | 0.450 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.380 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.340 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.330 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.280 | Inavolisib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.270 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.250 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.240 | Idelalisib | — uncovered |
| COMPLEMENT | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.210 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.210 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.160 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.150 | Inavolisib | — uncovered |